Cravatex

Why is Cravatex Ltd falling/rising?

As of 10-Aug, Cravatex Ltd's stock price is at 345.05, reflecting a decline of 0.71%. The stock has consistently underperformed, losing 13.89% over the past month and 28.31% over the past year, while trading below its moving averages, indicating a bearish trend.

As of 10-Aug, Cravatex Ltd's stock price is falling, currently at 345.05, which reflects a decrease of 2.45 or 0.71%. The stock has been underperforming, having lost 3.94% over the last four days, and it has consistently declined for four consecutive days. In terms of broader performance, the stock has decreased by 13.89% over the past month and 28.31% over the past year, contrasting sharply with the Sensex, which has gained 1.25% in the last month and only lost 1.65% over the past year.<BR><BR>Additionally, Cravatex is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 110.07% against the 5-day average, the overall performance remains weak. The stock's performance today has underperformed its sector by 0.73%, further contributing to the downward pressure on its price.

Which are the latest news on Cravatex?

Should I buy, sell or hold Cravatex Ltd?

How big is Cravatex?

As of 10th June, Cravatex Ltd has a market capitalization of 91.00 Cr, with recent net sales of 150.88 Cr and a net profit of 6.80 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Cravatex Ltd has a market capitalization of 91.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 150.88 Cr, while the sum of Net Profit for the same period is 6.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is for March 2025, with Shareholder's Funds amounting to 106.43 Cr and Total Assets valued at 140.70 Cr.

Who are in the management team of Cravatex?

The management team of Cravatex includes Rajesh Batra (Chairman & Managing Director), S D Israni, N Santhanam, and Pheroza Jimmy Bilimoria (Independent Directors), Sudhanshu Namdeo (Company Secretary), Divakar Ganapati Kamath (Executive Director & CFO), and Rohan Batra (Director). They are responsible for overseeing the company's operations and strategic direction.

The management team of Cravatex includes the following individuals:<BR><BR>1. **Rajesh Batra** - Chairman & Managing Director<BR>2. **S D Israni** - Independent Director<BR>3. **Sudhanshu Namdeo** - Company Secretary & Compliance Officer<BR>4. **N Santhanam** - Independent Director<BR>5. **Pheroza Jimmy Bilimoria** - Independent Director<BR>6. **Divakar Ganapati Kamath** - Executive Director & CFO<BR>7. **Rohan Batra** - Director<BR><BR>This team plays a crucial role in overseeing the company's operations and strategic direction.

Who are the peers of the Cravatex?

Cravatex's peers include Goyal Aluminiums, Lykis, Mehai Technology, Ashnisha Industries, Sunrise Efficiency, Fervent Synergies, Variman Global, and Uma Exports. In terms of management risk, growth, and capital structure, Cravatex shows average performance, with a 1-year return of -22.72%.

Peers: The peers of Cravatex are Goyal Aluminiums, Lykis, Mehai Technology, Ashnisha Indus., Sunrise Efficie., Fervent Synerg., Variman Global, and Uma Exports.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sunrise Efficie., while Average management risk is found at Goyal Aluminiums and Cravatex. Below Average management risk is noted at Lykis, Mehai Technology, Ashnisha Indus., Fervent Synerg., Variman Global, and Uma Exports. In terms of growth, Excellent growth is seen at Mehai Technology, Good growth at Lykis and Fervent Synerg., while Average growth is found at Variman Global, and Below Average growth is noted at Goyal Aluminiums, Cravatex, Ashnisha Indus., Sunrise Efficie., and Uma Exports. For capital structure, Excellent capital structure is present at Sunrise Efficie. and Variman Global, Good capital structure is observed at Goyal Aluminiums, while Below Average capital structure is noted at Lykis, Mehai Technology, Cravatex, Ashnisha Indus., Fervent Synerg., Uma Exports.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lykis at 35.87%, while the lowest is Mehai Technology at -88.10%. Cravatex's own 1-year return is -22.72%, which is higher than Mehai Technology's but lower than Lykis's. Additionally, peers with a negative six-month return include Sunrise Efficie., Mehai Technology, Fervent Synerg., Variman Global, and Uma Exports.

What does Cravatex do?

Cravatex Ltd is a micro-cap company in the Trading & Distributors industry, specializing in sports goods and fitness equipment, with a market cap of INR 91 Cr and reported net sales of 40 Cr and net profit of 2 Cr for the quarter ending March 2026. The company has a P/E ratio of 13.00 and a dividend yield of 3.57%.

Overview: <BR>Cravatex Ltd is a micro-cap company operating in the Trading & Distributors industry, specializing in sports goods and fitness equipment.<BR><BR>History: <BR>Cravatex Limited was incorporated in 1951 by Ram Kumar Batra and is part of The Batra Group. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 40 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 91 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 3.57% <BR>Debt-Equity: -0.80 <BR>Return on Equity: 5.69% <BR>Price to Book: 0.76<BR><BR>Contact Details: <BR>Address: Unit-201 2nd Flr Matulya Centr, S B Marg Lower Parel Mumbai Maharashtra : 400013 <BR>Email: investors@cravatex.com <BR>Website: http://www.cravatex.com

Are Cravatex Ltd latest results good or bad?

Cravatex Ltd's latest results are largely negative, showing a net profit increase of 11.11% to ₹1.60 crores, but a significant 34.72% decline in net sales to ₹39.51 crores and a negative operating margin of -1.52% indicate serious operational challenges. The company's reliance on non-operating income raises concerns about the sustainability of its profitability.

Cravatex Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q4 FY26, the company reported a net profit of ₹1.60 crores, which is an increase of 11.11% year-on-year. However, this positive aspect is overshadowed by a significant decline in net sales, which fell by 34.72% to ₹39.51 crores compared to the same quarter last year.<BR><BR>While the profit after tax (PAT) margin improved to 4.05% from 2.38% year-on-year, the operating margin turned negative at -1.52%, a sharp decline from the previous year's positive margin. This indicates that the core operational performance is struggling, as the company generated an operating loss of ₹0.60 crores before accounting for other income.<BR><BR>Moreover, the reliance on non-operating income is concerning, as it constituted a staggering 147.32% of profit before tax, highlighting a dependency that raises questions about the sustainability of profitability. The overall financial health is further complicated by a five-year sales growth rate of -19.56%, indicating a long-term trend of revenue contraction.<BR><BR>In summary, while there are some improvements in profit margins, the sharp decline in sales and operational losses signal significant challenges for Cravatex Ltd, making the latest results more negative than positive.

How has been the historical performance of Cravatex?

Cravatex has experienced significant declines in net sales and profitability, with net sales dropping from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, and operating profit margins turning negative. Despite a reduction in total liabilities, the company has struggled to maintain revenue and profitability over recent years.

Answer:<BR>The historical performance of Cravatex shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Cravatex's net sales have seen a downward trend from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, indicating a substantial decline in revenue. The total operating income followed a similar pattern, decreasing from 778.67 Cr in Mar'20 to 173.76 Cr in Mar'25. The company's operating profit margins have been negative in recent years, with an operating profit of -1.69 Cr in Mar'25, compared to a positive 11.30 Cr in Mar'22. Profit before tax also dropped significantly from 58.33 Cr in Mar'23 to 6.37 Cr in Mar'25, while profit after tax remained stagnant at 4.83 Cr for both Mar'25 and Mar'24, down from 58.93 Cr in Mar'23. On the balance sheet, total liabilities decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, reflecting a reduction in long-term borrowings, which were eliminated by Mar'25. Total assets also decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, with cash and cash equivalents showing a slight increase to 75.45 Cr in Mar'25 from 56.32 Cr in Mar'23. Overall, Cravatex has faced challenges in maintaining revenue and profitability, while managing its liabilities effectively.

When is the next results date for Cravatex?

The next results date for Cravatex is 14 November 2025.

The next results date for Cravatex is scheduled for 14 November 2025.

Is Cravatex overvalued or undervalued?

As of April 25, 2023, Cravatex is considered a risky investment due to its overvaluation, reflected in a PE ratio of 23.05, negative ROCE of -21.02%, and unfavorable comparisons to peers, despite a recent stock return of 11.28%.

As of 25 April 2023, Cravatex's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 23.05, a Price to Book Value of 1.04, and a concerning ROCE of -21.02%. <BR><BR>When compared to peers, Cravatex's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while PTC India is valued attractively at a PE of 9.02. The negative EV to EBIT and EV to EBITDA ratios of -6.24 and -11.70, respectively, further underscore the company's financial struggles. Despite a recent stock return of 11.28% over the past month, which outperformed the Sensex's 3.86%, the overall indicators suggest that Cravatex is not a favorable investment at its current price of 439.00.

What is the technical trend for Cravatex?

As of April 28, 2025, Cravatex's technical trend is mildly bearish, influenced by mixed signals from moving averages and indicators, with weekly MACD and Bollinger Bands showing mild bullishness while monthly indicators reflect bearishness.

As of 28 April 2025, the technical trend for Cravatex has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands on the weekly chart are mildly bullish, but the monthly view is bearish. Daily moving averages are mildly bearish, and the KST is mildly bullish on the weekly but bearish on the monthly. Dow Theory reflects a mildly bearish trend on the weekly and no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from the moving averages and the monthly indicators.

Who are the top shareholders of the Cravatex?

The top shareholder of Cravatex is R B Fitness And Trading Private Limited, holding 74.36% of the shares. Individual investors own 21.13%, while the highest public shareholder is Mahesh Parameswaran Nair with 2.01%.

The top shareholders of Cravatex are primarily the promoters, with R B Fitness And Trading Private Limited holding the largest stake at 74.36%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Mahesh Parameswaran Nair, who owns 2.01%. Additionally, individual investors collectively hold 21.13% of the shares.

What is the bonus history of the Cravatex?

Cravatex Ltd had a bonus issue of 1:1 announced on July 15, 2011, with a record date of July 19, 2011, allowing shareholders to receive one additional share for each share held.

Cravatex Ltd has a bonus history that includes a 1:1 bonus issue announced on July 15, 2011. The record date for this bonus was July 19, 2011. This means that shareholders received one additional share for every share they held as of the record date.

Has Cravatex declared dividend?

Cravatex Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of July 30, 2024. The company has shown strong long-term growth, achieving a total return of 62.43% over the past five years.

Cravatex Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: Jul-30-2024<BR><BR>Dividend Yield: 0.7%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cravatex experienced a price return of -2.99% with no dividend return, resulting in a total return of -2.99%.<BR><BR>Over the past year, the company had a price return of 6.39% and a dividend return of 0.75%, leading to a total return of 7.14%.<BR><BR>In the 2-year period, Cravatex achieved a price return of 44.52% and a dividend return of 1.08%, culminating in a total return of 45.6%.<BR><BR>For the 3-year period, the price return was 15.36% with a dividend return of 2.34%, resulting in a total return of 17.7%.<BR><BR>In the last 4 years, Cravatex saw a price return of 47.98% and a dividend return of 3.48%, giving a total return of 51.46%.<BR><BR>Over the 5-year period, the company recorded a price return of 58.5% along with a dividend return of 3.93%, resulting in a total return of 62.43%.<BR><BR>Overall, Cravatex has declared a significant dividend, and while the recent total returns show variability, the long-term performance indicates strong growth, particularly over the 5-year period.